Overview

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

Status:
Completed

Trial end date:
2020-08-11

Target enrollment:

Participant gender:

Summary

This is a First In Human study designed to assess the safety, tolerability and pharmacokinetics of EIDD-2801 in healthy human volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Ridgeback Biotherapeutics, LP